Phio Pharmaceuticals Corp is a biotechnology company focused on the development of innovative therapies for cancer treatment
The company specializes in leveraging its proprietary delivery platform to enhance the effectiveness of immune-based therapies, particularly in the area of adoptive cell therapy. By utilizing their unique technology, Phio aims to create treatments that can empower the body’s immune system to better target and destroy cancer cells, ultimately improving patient outcomes and offering new hope in the fight against various types of cancer.
Marlborough, Massachusetts--(Newsfile Corp. - February 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQPHIO) is a clinical-stage biotechnology company developing therapeutics...
Marlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (NASDAQPHIO) is a clinical-stage biotechnology company developing therapeutics...
Marlborough, Massachusetts--(Newsfile Corp. - January 16, 2025) - Phio Pharmaceuticals Corp. (NASDAQPHIO), a clinical-stage biotechnology company that develops therapeutics...
Marlborough, Massachusetts--(Newsfile Corp. - January 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQPHIO), a clinical-stage biotechnology company that develops therapeutics...
Marlborough, Massachusetts--(Newsfile Corp. - January 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQPHIO), a clinical-stage biotechnology company that develops therapeutics...
CEO Robert Bitterman highlighted the potential of Phio’s proprietary INTASYL RNAi technology, which targets proteins that hinder the body’s immune response to cancer.
As 2025 kicks off, several companies are standing out as stocks to watch, driven by groundbreaking technologies, strategic market positioning, and strong growth potential. From cutting-edge oncology treatments to defense technology innovations and wellness solutions, these companies are making waves across various sectors. Here's a closer look at stocks like Phio Pharmaceuticals (NASDAQPHIO), LightPath Technologies NASDAQ: LPTHNASDAQLPTH)(NASDAQ: KAVLNASDAQKAVL, and more, making headlines and capturing investor attention.
Phio Pharmaceuticals reports promising Phase 1b trial results for PH-762, showing complete tumor clearance in two patients with no significant adverse effects.
Marlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio Pharmaceuticals Corp. (NASDAQPHIO) is a clinical-stage biotechnology company developing therapeutics...
Marlborough, Massachusetts--(Newsfile Corp. - January 2, 2025) - Phio Pharmaceuticals Corp. (NASDAQPHIO) is a clinical-stage biotechnology company developing therapeutics...
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQPHIO), a clinical-stage biotechnology company that develops therapeutics...
